- Effect of Renal Impairment on the Pharmacokinetics and Safety of Axitinib. Targeted oncology. 2016 Academic Article GET IT
Axitinib in metastatic renal cell carcinoma: results of a pharmacokinetic and pharmacodynamic analysis.
Journal of clinical pharmacology.
Times cited: 57
Phase II, parallel-design study of preoperative combined modality therapy and the matrix metalloprotease (mmp) inhibitor prinomastat in patients with esophageal adenocarcinoma.
Investigational new drugs.
Times cited: 33